lundi 15 juin 2015

Onco Actu du 15 juin 2015

1. Biologie

Boob tubes: Breast grown in lab will test cancer treatments [New Scientist]

Study links gene to aggressive form of brain cancer [The Institute of Cancer Research]

3.1 Tabac

CDC, Sandman, and finding an "honest" appraisal of e-cigarettes [HealthNewsReview]

4.12 Biopsies liquides

Q&A With Elaine R. Mardis, PhD, on Integrating Clinical Genomics and Cancer Therapy [CANCER RESEARCH Catalyst]

4.7 Dép., diag. & prono. - Col de l'utérus

Cervical cancer 'not just a young woman's disease' [BBC News]

Older women 'ignoring cervical cancer danger' [The Guardian]

4.9 Dép., diag. & prono. - Sein

Breast-Cancer Screening [Now@NEJM]

5.2 Pharma

Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study [The BMJ]

FDA: Drug Companies Routinely Hide The Reasons Their Drugs Are Rejected From Investors [Forbes]

5.3 Traitements - FDA, EMA,...

How Often Are Drugs Withdrawn For Safety or Effectiveness Reasons (and How Many)? Not Too Often in Recent Years, But There is a Tranche of Withdrawals Historically [FDA Law Blog]

5.9.3 EHA

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial [ARIAD]

Agios' top cancer drug notches more remissions on the way to Phase III [FierceBiotech]

Results from Analyses of Revlimid® MCL-002 (SPRINT) Study Presented at EHA [Celgene]

Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CML [Novartis]

Novartis announces data show majority of patients with polycythemia vera treated with Jakavi® achieved long-term disease control [Novartis]

Novartis data at EHA show increased PFS benefit of Farydak® in new subgroup of patients with previously treated multiple myeloma [Novartis]

Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia [AbbVie]

Updated Results from MM-020/IFM 07-01 (First) Study of REVLIMID® Presented at European Hematology Annual Congress [Celgene]

Novartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemia [Novartis]

Agios leukemia drug demonstrates impressive response rate: study [Reuters]

6. Lutte contre les cancers

Athletes Colin Jackson and Donovan Bailey urge prostate cancer 'fear factor' [BBC News]

6.6 Publications

Nature retraction, resignation result after lung cancer cell lines “cannot be those specified" [Retraction Watch]

Cancer paper pulled due to "identical text" from one published 6 days prior; author objects [Retraction Watch]

6.7.2 Applis

The innovators: the app that allows patients to track their illnesses [The Guardian]